Correspondence regarding the importation of commercial data into Genbank, and Celera's plan to create their own databases. Adam Felsenfeld contacted other NHGRI staff out of concern over how Celera planned to sell information about disease risk to doctors, employers, and insurance companies. And Francis Collins hoped to encourage as much of Celera's human consensus sequence data as possible to end up in GenBank as their responsibility for the science community. Correspondence between Dr. Maria Freire of the NIH Office of Technology Transfer, Harold Varmus, Francis Collins, David Lipman of NLM, and Michael Gottesman also included creating a more detailed and narrower Memorandum of Understanding between Celera and NHGRI with legal framework so it was clear that Celera was a for-profit corporation but still should deposit proprietary and non-proprietary genomic information into GenBank to ensure public access while preserving Celera's commercial interests and patent rights. The NIH staff struggled to get Celera and Craig Venter to agree to this understanding, as Craig Venter did not want to agree to anything on paper, and their recent statements on data release reflected increasingly narrower conditions for access. Documents also include correspondence with Michael Morgan of the Wellcome Trust, and Richard Durbin of the Sanger Institute for feedback.